Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $41.00

Denali Therapeutics (NASDAQ:DNLI) had its price objective upped by Stifel Nicolaus from $34.00 to $41.00 in a report released on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Several other equities analysts also recently issued reports on the stock. Wedbush reduced their price objective on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Robert W. Baird lifted their target price on shares of Denali Therapeutics from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Thursday. Wolfe Research initiated coverage on Denali Therapeutics in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. UBS Group initiated coverage on Denali Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating on the stock. Finally, HC Wainwright raised their price objective on Denali Therapeutics from $32.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.82.

Denali Therapeutics Trading Down 8.0%

Shares of DNLI stock opened at $18.16 on Thursday. The firm has a 50-day moving average price of $20.43 and a 200 day moving average price of $17.85. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $23.77. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of -6.11 and a beta of 1.02. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same quarter last year, the firm earned ($0.67) EPS. Research analysts forecast that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Ryan J. Watts sold 35,198 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer directly owned 296,833 shares in the company, valued at approximately $4,897,744.50. This trade represents a 10.60% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This trade represents a 5.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 12.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DNLI. Vanguard Group Inc. grew its holdings in Denali Therapeutics by 8.9% during the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock valued at $215,586,000 after purchasing an additional 1,064,972 shares in the last quarter. Baillie Gifford & Co. increased its stake in Denali Therapeutics by 6.2% during the 4th quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock worth $203,253,000 after buying an additional 719,304 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Denali Therapeutics by 28.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after buying an additional 1,615,565 shares in the last quarter. Temasek Holdings Private Ltd lifted its holdings in Denali Therapeutics by 30.9% in the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after buying an additional 1,657,142 shares in the last quarter. Finally, State Street Corp boosted its position in Denali Therapeutics by 14.6% in the 4th quarter. State Street Corp now owns 6,263,371 shares of the company’s stock valued at $103,408,000 after buying an additional 799,110 shares during the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.